Spinal Muscular Atrophy Clinical Trials

Lessons Learned

S. T. Iannaccone, L. L. Nelson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

There are few completed randomized clinical trials for spinal muscular atrophy (SMA). There is no known effective treatment and most trials have been open label. However, much has been learned from those negative trials that helped improve trial design so that future studies will be powered and valid. Lessons learned include the fact that easy fatigability influences a subject's performance on outcome measures and that this fatigue can be induced by prolonged travel to the study site and prolonged procedures during the study visit. There is new and concerning use of social media by subjects and their families that could affect enrollment and outcomes; this demands new guidelines for trial participants and for investigators. Finally, it is very clear that all study groups must have received standard of care at the time of enrollment and throughout the study in order to avoid confounders of outcome measures.

Original languageEnglish (US)
Title of host publicationSpinal Muscular Atrophy
Subtitle of host publicationDisease Mechanisms and Therapy
PublisherElsevier Inc.
Pages423-428
Number of pages6
ISBN (Electronic)9780128036860
ISBN (Print)9780128036853
DOIs
StatePublished - Nov 4 2016

Fingerprint

Spinal Muscular Atrophy
Outcome Assessment (Health Care)
Clinical Trials
Naphazoline
Social Media
Standard of Care
Fatigue
Randomized Controlled Trials
Research Personnel
Guidelines

Keywords

  • Cochrane reviews
  • Fatigability
  • Outcome measures
  • Social media
  • Standard of care

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Iannaccone, S. T., & Nelson, L. L. (2016). Spinal Muscular Atrophy Clinical Trials: Lessons Learned. In Spinal Muscular Atrophy: Disease Mechanisms and Therapy (pp. 423-428). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-803685-3.00026-4

Spinal Muscular Atrophy Clinical Trials : Lessons Learned. / Iannaccone, S. T.; Nelson, L. L.

Spinal Muscular Atrophy: Disease Mechanisms and Therapy. Elsevier Inc., 2016. p. 423-428.

Research output: Chapter in Book/Report/Conference proceedingChapter

Iannaccone, ST & Nelson, LL 2016, Spinal Muscular Atrophy Clinical Trials: Lessons Learned. in Spinal Muscular Atrophy: Disease Mechanisms and Therapy. Elsevier Inc., pp. 423-428. https://doi.org/10.1016/B978-0-12-803685-3.00026-4
Iannaccone ST, Nelson LL. Spinal Muscular Atrophy Clinical Trials: Lessons Learned. In Spinal Muscular Atrophy: Disease Mechanisms and Therapy. Elsevier Inc. 2016. p. 423-428 https://doi.org/10.1016/B978-0-12-803685-3.00026-4
Iannaccone, S. T. ; Nelson, L. L. / Spinal Muscular Atrophy Clinical Trials : Lessons Learned. Spinal Muscular Atrophy: Disease Mechanisms and Therapy. Elsevier Inc., 2016. pp. 423-428
@inbook{48e52ea425a74f46a47e91ba9d793e55,
title = "Spinal Muscular Atrophy Clinical Trials: Lessons Learned",
abstract = "There are few completed randomized clinical trials for spinal muscular atrophy (SMA). There is no known effective treatment and most trials have been open label. However, much has been learned from those negative trials that helped improve trial design so that future studies will be powered and valid. Lessons learned include the fact that easy fatigability influences a subject's performance on outcome measures and that this fatigue can be induced by prolonged travel to the study site and prolonged procedures during the study visit. There is new and concerning use of social media by subjects and their families that could affect enrollment and outcomes; this demands new guidelines for trial participants and for investigators. Finally, it is very clear that all study groups must have received standard of care at the time of enrollment and throughout the study in order to avoid confounders of outcome measures.",
keywords = "Cochrane reviews, Fatigability, Outcome measures, Social media, Standard of care",
author = "Iannaccone, {S. T.} and Nelson, {L. L.}",
year = "2016",
month = "11",
day = "4",
doi = "10.1016/B978-0-12-803685-3.00026-4",
language = "English (US)",
isbn = "9780128036853",
pages = "423--428",
booktitle = "Spinal Muscular Atrophy",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Spinal Muscular Atrophy Clinical Trials

T2 - Lessons Learned

AU - Iannaccone, S. T.

AU - Nelson, L. L.

PY - 2016/11/4

Y1 - 2016/11/4

N2 - There are few completed randomized clinical trials for spinal muscular atrophy (SMA). There is no known effective treatment and most trials have been open label. However, much has been learned from those negative trials that helped improve trial design so that future studies will be powered and valid. Lessons learned include the fact that easy fatigability influences a subject's performance on outcome measures and that this fatigue can be induced by prolonged travel to the study site and prolonged procedures during the study visit. There is new and concerning use of social media by subjects and their families that could affect enrollment and outcomes; this demands new guidelines for trial participants and for investigators. Finally, it is very clear that all study groups must have received standard of care at the time of enrollment and throughout the study in order to avoid confounders of outcome measures.

AB - There are few completed randomized clinical trials for spinal muscular atrophy (SMA). There is no known effective treatment and most trials have been open label. However, much has been learned from those negative trials that helped improve trial design so that future studies will be powered and valid. Lessons learned include the fact that easy fatigability influences a subject's performance on outcome measures and that this fatigue can be induced by prolonged travel to the study site and prolonged procedures during the study visit. There is new and concerning use of social media by subjects and their families that could affect enrollment and outcomes; this demands new guidelines for trial participants and for investigators. Finally, it is very clear that all study groups must have received standard of care at the time of enrollment and throughout the study in order to avoid confounders of outcome measures.

KW - Cochrane reviews

KW - Fatigability

KW - Outcome measures

KW - Social media

KW - Standard of care

UR - http://www.scopus.com/inward/record.url?scp=85027278745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027278745&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-803685-3.00026-4

DO - 10.1016/B978-0-12-803685-3.00026-4

M3 - Chapter

SN - 9780128036853

SP - 423

EP - 428

BT - Spinal Muscular Atrophy

PB - Elsevier Inc.

ER -